CD20 antibody-conjugated immunoliposomes for targeted chemotherapy of melanoma cancer initiating cells

Journal of Biomedical Nanotechnology

Volumn 11, Issue 11, 2015, Pages 1927-1946

  Song, Hao ^a,b,e   Su, Xiao ^a   Yang, Kaixuan ^a   Niu, Fangfang ^a   Li, Jun ^b   Song, Jinjing ^a   Chen, Huaiwen ^a   Li, Bohua ^a,b   Li, Wei ^a,b   Qian, Weizhu ^a,b   Cao, Xuesong ^b   Guo, Shangjing ^b   Dai, Jianxin ^a,b   Feng, Si Shen ^c,d   Guo, Yajun ^a,b   Yin, Chuan ^f   Gao, Jie ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b LIAOCHENG UNIVERSITY   (China)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d Suzhou NanoStar Biopharm Inc Ltd   (China)

^e LIAOCHENG PEOPLE'S HOSPITAL   (China)

^f SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer Initiating Cells; CD20; Immunoliposomes; Melanoma; Vincristine

Indexed keywords

ANTIBODIES; CELLS; CHEMOTHERAPY; CYTOLOGY; DERMATOLOGY; DISEASES; DRUG PRODUCTS; DRUG THERAPY; ENCAPSULATION; LIPOSOMES; PARTICLE SIZE; STEM CELLS;

CD20; CHINESE HAMSTER OVARY CELLS; DRUG ENCAPSULATION EFFICIENCY; IMMUNOLIPOSOMES; MELANOMA; TARGETED CHEMOTHERAPY; THERAPEUTIC EFFECTS; VINCRISTINE;

ONCOLOGY;

CD20 ANTIBODY; CD20 ANTIGEN; IMMUNOLIPOSOME; VINCRISTINE; ANTINEOPLASTIC AGENT; LIPOSOME;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INITIATING CELL; CANCER SIZE; CHO CELL LINE; CONJUGATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; ZETA POTENTIAL; ANIMAL; BODY WEIGHT; CELL LINE; CELL PROLIFERATION; CHEMISTRY; CRICETULUS; DRUG EFFECTS; DRUG SCREENING; HAMSTER; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CELL LINE; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; LIPOSOMES; MELANOMA; MICE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84956580912     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.2129     Document Type: Article

References (41)

1. B. B. Zhou, H. Zhang, M. Damelin, K. G. Geles, J. C. Grindley, and P. B. Dirks, Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 8, 806 (2009).
2. J. F. Thompson, R. A. Scolyer, and R. F. Kefford, Cutaneous melanoma. Lancet. 365, 687 (2005).
3. S. E. Zabierowski and M. Herlyn, Melanoma stem cells: The dark seed of melanoma. J. Clin. Oncol. 26, 2890 (2008).
4. D. Fang, T. K. Nguyen, K. Leishear, R. Finko, A. N. Kulp, S. Hotz, P. A. Van Belle, X. Xu, D. E. Elder, and M. Herlyn, A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 65, 9328 (2005).
5. P. Schmidt, C. Kopecky, A. Hombach, P. Zigrino, C. Mauch, and H. Abken, Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc. Natl. Acad. Sci. USA 108, 2474 (2011).
6. A. Pinc, R. Somasundaram, C. Wagner, M. Hormann, G. Karanikas, A. Jalili, W. Bauer, P. Brunner, K. Grabmeier-Pfistershammer, M. Gschaider, C. Y. Lai, M. Y. Hsu, M. Herlyn, G. Stingl, and S. N. Wagner, Targeting CD20 in melanoma patients at high risk of dis ease recurrence. Mol. Ther. 20, 1056 (2012).
7. T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, Stem cells, cancer, and cancer stem cells. Nature 414, 105 (2001).
8. D. G. Maloney, Anti-CD20 antibody therapy for B-cell lymphomas. N. Engl. J. Med. 366, 2008 (2012).
9. P. McLaughlin, A. J. Grillo-Lopez, B. K. Link, R. Levy, M. S. Czuczman, M. E. Williams, M. R. Heyman, I. Bence-Bruckler, C. A. White, F. Cabanillas, V. Jain, A. D. Ho, J. Lister, K. Wey, D. Shen, and B. K. Dallaire, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825 (1998).
10. B. Coiffier, C. Haioun, N. Ketterer, A. Engert, H. Tilly, D. Ma, P. Johnson, A. Lister, M. Feuring-Buske, J. A. Radford, R. Capdev-ille, V. Diehl, and F. Reyes, Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92, 1927 (1998).
11. M. B. Lens and T. G. Eisen, Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin. Pharmacother. 4, 2205 (2003).
12. A. Orouji, S. Goerdt, and J. Utikal, Systemic therapy of non-resectable metastatic melanoma. Cancers (Basel) 2, 955 (2010).
13. V. P. Torchilin, Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145 (2005).
14. A. Bedikian, A. Vardeleon, and T. Smith, Pharmacokinetics (PK) study of sphingosomal vincristine (SV) in patients with metastatic melanoma (MM), ASCO Annual Meeting Proceedings, New Orleans, LA, USA (2004), p. 2038.
15. A. Y. Bedikian, N. E. Papadopoulos, K. B. Kim, A. Vardeleon, T. Smith, S. B. Lu, and R. Deitcher, A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma. Melanoma. Res. 18, 400 (2008).
16. D. Y. Hueng, H. K. Sytwu, S. M. Huang, C. Chang, and H. I. Ma, Isolation and characterization of tumor stem-like cells from human meningiomas. J. Neurooncol. 104, 45 (2011).
17. A. S. Manjappa, K. R. Chaudhari, M. P. Venkataraju, P. Dantuluri, B. Nanda, C. Sidda, K. K. Sawant, and R. S. Murthy, Antibody derivatization and conjugation strategies: Application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J. Control. Release 150, 2 (2011).
18. Y. Matsumura, M. Gotoh, K. Muro, Y. Yamada, K. Shirao, Y. Shimada, M. Okuwa, S. Matsumoto, Y. Miyata, H. Ohkura, K. Chin, S. Baba, T. Yamao, A. Kannami, Y. Takamatsu, K. Ito, and K. Takahashi, Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol. 15, 517 (2004).
19. C. Mamot, R. Ritschard, A. Wicki, G. Stehle, T. Dieterle, L. Bubendorf, C. Hilker, S. Deuster, R. Herrmann, and C. Rochlitz, Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: A phase 1 dose-escalation study. Lancet Oncol. 13, 1234 (2012).
20. P. Sapra, P. Tyagi, and T. M. Allen, Ligand-targeted liposomes for cancer treatment. Curr. Drug Deliv. 2, 369 (2005).
21. P. Sapra and T. M. Allen, Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin. Cancer Res. 10, 2530 (2004).
22. G. J. Charrois and T. M. Allen, Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim. Biophys Acta 1663, 167 (2004).
23. J. M. Adams and A. Strasser, Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res. 68, 4018 (2008).
24. C. H. Wang, S. H. Chiou, C. P. Chou, Y. C. Chen, Y. J. Huang, and C. A. Peng, Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine (Lond.) 7, 69 (2011).
25. A. P. Johnston, M. M. Kamphuis, G. K. Such, A. M. Scott, E. C. Nice, J. K. Heath, and F. Caruso, Targeting cancer cells: Controlling the binding and internalization of antibody-functionalized capsules. ACS. Nano. 6, 6667 (2012).
26. J. Gao, H. Chen, Y. Yu, J. Song, H. Song, X. Su, W. Li, X. Tong, W. Qian, H. Wang, J. Dai, and Y. Guo, Inhibition of hepatocel-lular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA. Biomaterials 34, 10084 (2013).
27. J. Gao, Y. Xia, H. Chen, Y. Yu, J. Song, W. Li, W. Qian, H. Wang, J. Dai, and Y. Guo, Polymer-lipid hybrid nanoparticles conjugated with anti-EGF receptor antibody for targeted drug delivery to hepa-tocellular carcinoma. Nanomedicine (Lond.) 9, 279 (2014).
28. J. Gao, Y. Yu, Y. Zhang, J. Song, H. Chen, W. Li, W. Qian, L. Deng, G. Kou, J. Chen, and Y. Guo, EGFR-specific PEGylated immuno-liposomes for active siRNA delivery in hepatocellular carcinoma. Biomaterials 33, 270 (2012).
29. V. P. Torchilin and V. Weissig, Liposomes: A Practical Approach, 2nd edn., Oxford University Press, New York, NY, USA (2003).
30. N. L. Boman, D. Masin, L. D. Mayer, P. R. Cullis, and M. B. Bally, Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 54, 2830 (1994).
31. J. C. Stewart, Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 104, 10 (1980).
32. M. R. Smith, Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 22, 7359 (2003).
33. P. Sapra and T. M. Allen, Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 62, 7190 (2002).
34. K. L. Mealey, N. C. Northrup, and S. A. Bentjen, Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. J. Am. Vet. Med. Assoc. 223, 1453 (2003).
35. J. Gao, S. S. Feng, and Y. Guo, Nanomedicine against multidrug resistance in cancer treatment. Nanomedicine (Lond.) 7, 465 (2012).
36. J. E. Visvader and G. J. Lindeman, Cancer stem cells: Current status and evolving complexities. Cell Stem Cell 10, 717 (2012).
37. C. L. Chaffer, N. D. Marjanovic, T. Lee, G. Bell, C. G. Kleer, F. Reinhardt, A. C. D'Alessio, R. A. Young, and R. A. Weinberg, Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 154, 61 (2013).
38. S. J. Grainger, J. V. Serna, S. Sunny, Y. Zhou, C. X. Deng, and M. E. El-Sayed, Pulsed ultrasound enhances nanoparticle penetration into breast cancer spheroids. Mol. Pharm. 7, 2006 (2010).
39. K. N. Sugahara, T. Teesalu, P. P. Karmali, V. R. Kotamraju, L. Agemy, D. R. Greenwald, and E. Ruoslahti, Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328, 1031 (2010).
40. J. Gao, S. S. Feng, and Y. Guo, Nanomedicine for treatment of cancer stem cells. Nanomedicine (Lond.) 9, 181 (2014).
41. A. M. Nystrom and B. Fadeel, Safety assessment of nanomaterials: Implications for nanomedicine. J. Control. Release 161, 403 (2012).